

Tamgiblimab Biosimilar - Research Grade

Product Code: ICH5279

More Information

Species Reactivity: Human

Target: TIGIT

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Tamgiblimab Biosimilar - Research Grade

Antibodies against the same target: [Anti-Human TIGIT \(4E1.2\) In Vivo Antibody - Low Endotoxin \(ICH1219\)](#), [Anti-Mouse TIGIT \(1G9\) In Vivo Antibody - Low Endotoxin \(ICH1220\)](#), [Tiragolumab Biosimilar - Research Grade \(ICH5078\)](#), [Vibostolimab Biosimilar - Research Grade \(ICH5159\)](#), [Belrestotug Biosimilar - Research Grade \(ICH5384\)](#), [Dargistotug Biosimilar - Research Grade \(ICH5465\)](#), [Domvanalimab Biosimilar - Research Grade \(ICH5486\)](#), [Etigilimab Biosimilar - Research Grade \(ICH5536\)](#), [Lancastotug Biosimilar - Research Grade \(ICH5623\)](#), [Ociperlimab Biosimilar - Research Grade \(ICH5722\)](#), [Ralzapastotug Biosimilar - Research Grade \(ICH5803\)](#), [Renvistobart Biosimilar - Research Grade \(ICH5816\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q495A1

Shipping Conditions: Blue ice

background: Tamgiblimab Biosimilar (Research Grade) is an unconjugated, non-therapeutic research analog of the anti-TIGIT antibody tamgiblimab (originator code IBI939,

Innovent Biologics), a fully human IgG4-kappa monoclonal originally developed as a checkpoint immunotherapy for solid tumors, typically explored in combination with PD-1/PD-L1 blockade. This product is built to recapitulate the binding characteristics of the originator against its target, human TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains), and is supplied strictly for research use only. It is not a clinical drug and is not intended for therapeutic, diagnostic, or human use. Matching the originator, it carries a human IgG4-kappa framework, which limits Fc effector engagement relative to IgG1-based checkpoint agents. The biosimilar is intended as a consistent, well-characterized reagent for studies of TIGIT biology, ligand-blockade, and checkpoint-pathway crosstalk, and as a reference or control antibody in assay development. As a human-targeted molecule, it is most suited to in-vitro and functional work rather than mouse in-vivo dosing. Available in bulk quantities with low endotoxin research-grade specifications. TIGIT is an inhibitory immune checkpoint receptor expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells. It binds the ligands CD155 (PVR) and CD112 (PVRL2/nectin-2), which are frequently overexpressed on tumor cells and antigen-presenting cells. Engagement of TIGIT delivers inhibitory signals that dampen T-cell and NK-cell activation and promote functional exhaustion of tumor-infiltrating lymphocytes. TIGIT also competes with the co-stimulatory receptor CD226 (DNAM-1) for the same ligands, further tilting the balance toward immunosuppression, and it can enhance Treg suppressive activity. Because CD155 is upregulated in many malignancies, the TIGIT axis is a prominent target in cancer immunotherapy, often pursued alongside PD-1/PD-L1 blockade. Antibodies that block TIGIT-ligand interactions aim to restore cytotoxic T-cell and NK-cell function within the tumor microenvironment.

Other names: V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

Specificity: Detects human TIGIT

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method



Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks